UBS Group reiterated their buy rating on shares of GlaxoSmithKline (LON:GSK) in a report issued on Monday morning, Borsen Zeitung reports. UBS Group currently has a GBX 1,900 ($24.83) price objective on the stock.
Other research analysts have also recently issued reports about the stock. Goldman Sachs Group set a GBX 1,900 ($24.83) target price on shares of GlaxoSmithKline and gave the company a buy rating in a report on Wednesday, October 30th. Credit Suisse Group lifted their price target on shares of GlaxoSmithKline from GBX 1,700 ($22.21) to GBX 1,800 ($23.52) and gave the company a neutral rating in a research report on Thursday, October 31st. Barclays restated an equal weight rating on shares of GlaxoSmithKline in a report on Monday, November 18th. DZ Bank raised their price objective on GlaxoSmithKline from GBX 1,850 ($24.17) to GBX 2,000 ($26.13) and gave the company a buy rating in a research note on Thursday, October 31st. Finally, JPMorgan Chase & Co. set a GBX 1,700 ($22.21) price objective on GlaxoSmithKline and gave the stock a neutral rating in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of GBX 1,783 ($23.30).
Shares of LON GSK opened at GBX 1,710.80 ($22.35) on Monday. The stock has a market capitalization of $86.35 billion and a price-to-earnings ratio of 18.74. GlaxoSmithKline has a 52 week low of GBX 1,408.80 ($18.41) and a 52 week high of GBX 1,796.40 ($23.47). The firm has a 50-day moving average price of GBX 1,714.22 and a 200 day moving average price of GBX 1,654.88. The company has a quick ratio of 0.50, a current ratio of 0.82 and a debt-to-equity ratio of 183.00.
In related news, insider Vivienne Cox acquired 308 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of GBX 1,725 ($22.54) per share, for a total transaction of £5,313 ($6,942.38). Insiders have purchased a total of 330 shares of company stock valued at $568,756 over the last 90 days.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Article: What is Call Option Volume?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.